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Background: Higher statin intensity is associated with a lower risk of mortality in patients with cardiovascular disease. 
However, little is known about the relationship between statin intensity and chronic kidney disease (CKD) progression.
Methods: We studied whether statin intensity affects kidney function decline in 1,073 patients from the Korean 
Cohort Study for Outcome in Patients With Chronic Kidney Disease. The participants were classified based on statin 
intensity as low, moderate, and high. The study endpoint was CKD progression (composite of doubling of serum 
creatinine, ≥ 50% decrease in estimated glomerular filtration rate [eGFR] from baseline, or end-stage renal disease).
Results: The mean age was 56.0 ± 11.4 years, and 665 (62.0%) participants were male. The mean eGFR was 51.7 ± 
26.7 mL/min/1.73 m2; there were no differences in baseline eGFR among statin intensity groups. During the median 
follow-up of 39.9 (25.4-61.6) months, 255 (23.8%) patients reached the study endpoint. In multivariable Cox model 
after adjustment of confounders, the hazard ratios (95% confidence interval) for adverse kidney outcome were 0.97 
(0.72-1.30) and 1.15 (0.60-2.20) in moderate and high statin intensity groups, respectively, compared with the low 
intensity group. In addition, no significant association was observed in subgroups stratified by age, sex, eGFR, and 
atherosclerotic cardiovascular disease risk scores.
Conclusion: We did not observe any significant association between intensity of statin therapy and progression of CKD. 
Long-term kidney outcomes may not be affected by statin intensity.
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Introduction
Chronic kidney disease (CKD) is a major health prob-
lem worldwide [1,2]. Patients with CKD have increased 
risk of end-stage renal disease (ESRD), cardiovascular 
disease, and all-cause mortality [2-4]. Risk factors for 
development and progression of CKD are similar to 
those implicated in cardiovascular disease, including 
hypertension, diabetes, and dyslipidemia [5-7]. Among 
these factors, abnormal lipid metabolism is common in 
patients with kidney disease [8]. Previous experimental 
studies have shown that hyperlipidemia is associated 
with kidney injury [9,10]. Several epidemiologic studies 
demonstrated that dyslipidemia is significantly associ-
ated with increased risk of reduced kidney function or 
greater decline in estimated glomerular filtration rate 
(eGFR) in the general population without kidney disease 
[11,12]. However, the effects of statins on kidney disease 
progression in patients with CKD remain controversial 
[13].
High-intensity statin therapy can reduce the risk for car-
diovascular events regardless of baseline risk [14,15]. The 
2013 American College of Cardiology/American Heart As-
sociation (ACC/AHA) lipid guidelines recommend statin 
dosing in adults based on intensity, rather than targeting 
specific low-density lipoprotein cholesterol (LDL-C) con-
centration. The 2013 Kidney Disease: Improving Global 
Outcomes (KDIGO) lipid guidelines also recommend use 
of statins for most patients with CKD aged ≥ 50 years and 
with eGFR < 60 mL/min/1.73 m2, in light of their high car-
diovascular risk, based on previous randomized trial data 
on lipid-lowering therapy in CKD [16,17]. However, there 
have been conflicting results regarding the beneficial ef-
fect of statins on kidney function. Moreover, observation-
al studies have reported an increased risk of acute kidney 
injury after initiation of high-intensity statin [18,19], rais-
ing concern for worsening kidney function in patients 
with CKD and long-term use of high-intensity statin. It 
is well-known that statin therapy in patients with CKD is 
not as effective as in people without CKD. The reason for 
this is not clear, but we hypothesized that statin intensity 
might modify the relationship between statin use and ad-
verse clinical outcomes in patients with CKD.
Thus, we aimed to investigate whether higher-intensity 
statin therapy is associated with lower risk of CKD pro-
gression in Korean adults with CKD. 
Methods
Study participants
The Korean Cohort Study for Outcome in Patients With 
Chronic Kidney Disease (KNOW-CKD) is a prospective 
nationwide cohort study investigating various clinical 
courses and risk factors for CKD progression in Korean 
patients. Patients aged between 20 and 75 years with CKD 
stages from 1 to 5 before dialysis who voluntarily provided 
informed consent were enrolled from nine tertiary-care 
general hospitals throughout Korea between June 2011 
and February 2016. The study rationale, design, methods, 
and protocol summary are provided in detail elsewhere 
(NCT01630486 at http://www.clinicaltrials.gov) [20]. 
Among 2,238 patients in the KNOW-CKD cohort, 1,085 
with baseline eGFR < 15 mL/min/1.73 m2 and missing 
data regarding statin therapy or lipid profiles were ex-
cluded. Finally, 1,073 patients were included in the pres-
ent analysis (Fig. 1). All included patients provided writ-
ten informed consent, and the study was approved by the 
institutional review board of each participating center. All 
investigators conducted this study in accordance with the 
guidelines of the 2008 Declaration of Helsinki.
Data collection
Demographic data were collected from all patients, in-
cluding age, sex, smoking status, social history, and medi-
cal history. Smoking status was classified as never, past, or 
current. Education level was categorized as low, less than 
KoreaN cohort study for Outcome in patients With Chronic Kidney
Disease (KNOW-CKD) cohort study (n = 2,238)
Exclusion (n = 1,165)
1) Estimated glomerular filtration rate < 15 mL/min/1.73 m
2) Missing baseline data about statin use (n = 1,085)
3) Missing baseline data about lipid profile (n = 66)
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1,073 patients were classified into three groups according







Figure 1. Study participants. 
CKD, chronic kidney disease.
Jhee, et al. Intensity of statin therapy and CKD
95www.krcp-ksn.org
middle school; middle, middle school; and high, more 
than middle school. Income level was divided into three 
groups: low, < $1,200 per month; middle, $1,200 to $3,800 
per month; and high, ≥ $3,800 per month. Anthropomet-
ric data including height and weight were collected upon 
enrollment. Body mass index (BMI) was calculated by 
dividing initial body weight by height in meters squared. 
After 5 minutes of seated rest, blood pressure (BP) was 
measured using an electronic sphygmomanometer. Hy-
pertension was defined as history of physician-diagnosed 
hypertension, systolic BP (SBP) ≥ 140 mmHg, diastolic BP ≥ 
90 mmHg, or use of antihypertensive drugs. Diabetes was 
defined as history of physician-diagnosed diabetes, fast-
ing glucose ≥ 126 mg/dL, post-load glucose level ≥ 200 
mg/dL, HbA1c ≥ 6.5%, or use of insulin or oral antidiabet-
ic drugs. Charlson Comorbidity Index was assessed using 
the method described previously [21]. The 10-year athero-
sclerotic cardiovascular disease (ASCVD) risk scores were 
calculated according to the risk assessment equation from 
the 2013 ACC/AHA guidelines [22]. After an overnight 
fast, venous samples were collected to determine hemo-
globin, serum urea nitrogen, creatinine, fasting plasma 
glucose, albumin, calcium, phosphate, total cholesterol, 
triglycerides (TG), high-density lipoprotein cholesterol, 
LDL-C, and high-sensitivity C-reactive protein levels. Se-
rum creatinine was measured by an isotope dilution mass 
spectrometry-traceable method at the central laboratory 
(Lab Genomics, Seoul, Korea). The CKD Epidemiology 
Collaboration equation was used to determine eGFR [23]. 
The second voided or random urine was collected, and 
samples were immediately sent to the central laboratory. 
Proteinuria was determined by 24-hour urinary protein 
excretion test (g/24 hr).
Intensity of statin therapy
Intensity of statin therapy was defined based on the 
expected LDL-C reduction indicated in clinical trials, as 
summarized in the 2013 ACC/AHA guidelines (Supple-
mentary Table 1; available online) [14]. 
Study outcomes
Study participants were followed-up until March 31, 
2018. The study endpoint was a composite of doubling 
of serum creatinine, ≥ 50% decline in eGFR, initiation of 
dialysis, or kidney transplantation.
Statistical analysis
All statistical analyses were performed using IBM SPSS 
software for Windows ver. 24.0 (IBM Corp., Armonk, NY, 
USA), SAS software ver. 9.2 (SAS Institute Inc., Cary, NC, 
USA), and R software ver. 3.3.1 (http://www.R-project.
org). Continuous variables were expressed as mean ± 
standard deviation or median and interquartile range. 
Categorical variables were expressed as frequency with 
percentage. All continuous variables were tested for 
normality before statistical analysis. The Kolmogorov-
Smirnov test was performed to determine the normality 
of parameter distribution. Comparisons between groups 
were performed using analysis of variance with a normal 
distribution and the chi-square test or Fisher’s exact test 
for categorical variables. Data that did not show a normal 
distribution were compared using the Kruskal-Wallis test. 
To evaluate the association between statin intensity and 
CKD progression, multivariable Cox regression analysis 
was performed. Variables that were significant in uni-
variable analysis (P < 0.05) or clinically important were 
included for adjustment. The results were presented as 
hazard ratios (HRs) and 95% confidence intervals (CIs). 
Participants who were lost to follow-up were censored at 




The baseline characteristics of participants according 
to statin therapy intensity-based group are described in 
Table 1. Totals of 427 (39.8%), 596 (55.5%), and 50 (4.7%) 
participants were classified into low-, moderate-, and 
high-intensity statin groups, respectively. The mean age 
of participants was 56.0 ± 11.39 years, and 665 (62.0%) 
were male. The mean eGFR was 51.7 ± 26.7 mL/min/1.73 
m2. Demographic data, including age, sex, smoking sta-
tus, marital status, education status, income status, BMI, 
and BP, showed no significant differences among the 
groups. The most common cause of CKD in study par-
ticipants was glomerulonephritis, followed by diabetes 
and hypertension. However, no differences were found 
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Table 1. Baseline characteristics of participants according to statin therapy intensity
Characteristic Total (n = 1,073)
Statin therapy intensity group
Low (n = 427) Moderate (n = 596) High (n = 50) P value
Demographic data
   Age (yr) 56.0 ± 11.4 56.3 ± 11.1 55.8 ± 11.4 55.2 ± 13.4 0.70
   Male 665 (62.0) 273 (63.9) 357 (59.9) 35 (70.0) 0.63
   Smoker 0.24
      Never 557 (52.0) 215 (50.5) 318 (53.4) 24 (48.0)
      Past 179 (16.7) 64 (15.0) 103 (17.3) 12 (24.0)
      Current 333 (31.1) 145 (34.0) 174 (29.2) 14 (28.0)
   Married 916 (85.7) 364 (85.4) 511 (86.2) 41 (82.0) 0.91
   Education 0.73
      Low 274 (25.7) 97 (22.8) 167 (28.2) 10 (20.0)
      Intermediate 378 (35.4) 169 (39.7) 197 (33.3) 12 (24.0)
      High 416 (39.0) 160 (37.6) 228 (38.5) 28 (56.0)
   Income 0.49
      High 235 (22.4) 99 (24.1) 123 (21.0) 13 (26.0)
      Intermediate 559 (53.3) 214 (52.1) 322 (54.9) 23 (46.0)
      Low 254 (24.2) 98 (23.8) 142 (24.4) 14 (28.0)
   Body mass index (kg/m) 25.2 ± 5.7 25.3 ± 8.1 25.0 ± 3.2 26.2 ± 4.9 0.28
   Systolic BP (mmHg) 128.7 ± 15.9 129.8 ± 17.4 127.7 ± 15.0 130.1 ± 13.9 0.11
   Diastolic BP (mmHg) 76.5 ± 10.8 77.1 ± 11.8 76.3 ± 10.2 74.5 ± 10.5 0.20
Comorbidities
   Diabetes mellitus 440 (41.0) 176 (41.2) 241 (40.4) 23 (46.0) 0.86
   Hypertension 1,059 (98.7) 424 (99.3) 586 (98.3) 49 (98.0) 0.17
   Coronary artery disease 97 (9.0) 42 (9.8) 48 (8.1) 7 (14.0) 0.89
   Congestive heart failure 24 (2.2) 7 (1.6) 15 (2.5) 2 (4.0) 0.34
   Peripheral artery disease 57 (5.3) 21 (4.9) 34 (5.7) 2 (4.0) 0.81
Charlson comorbidity index 4.0 (2.0-5.0) 4.0 (2.0-5.0) 4.0 (2.0-5.0) 4.0 (0.7-5.0) 0.50
ASCVD risk score 7.8 (2.5-18.0) 7.9 (2.6-19.0) 7.6 (2.4-17.6) 9.1 (2.3-17.2) 0.55
Cause of CKD 0.82
   Diabetic nephropathy 291 (27.1) 119 (27.9) 156 (26.2) 16 (32.0)
   Hypertension 220 (20.5) 97 (22.7) 109 (18.3) 14 (28.0)
   Glomerulonephritis 401 (37.4) 142 (33.3) 242 (40.6) 17 (34.0)
   Polycystic kidney disease 92 (8.6) 40 (9.4) 51 (8.6) 1 (2.0)
   Others 69 (6.4) 29 (6.8) 38 (6.4) 2 (4.0)
Use of other lipid-lowering agent
   Ezetimibe 118 (11.0) 79 (18.5) 36 (6.0) 3 (6.0) <0.001
   Fibrate 20 (1.9) 6 (1.4) 10 (1.7) 4 (8.0) 0.05
   Nicotinic acid 2 (0.2) 1 (0.2) 1 (0.2) 0 (0.0) 0.71
Laboratory parameters
   eGFR (mL/min/1.73 m2) 51.7 ± 26.7 51.3 ± 26.2 52.1 ± 26.6 51.5 ± 32.0 0.88
   Proteinuria (g/24 hr) 0.70 (0.25-1.84) 0.65 (0.23-1.59) 0.72 (0.26-1.95) 1.37 (0.40-3.9) 0.01
   Hemoglobin (g/dL) 13.2 ± 7.1 13.5 ± 11.0 12.9 ± 1.9 13.0 ± 2.1 0.33
   Fasting plasma glucose (mg/dL) 115.6 ± 44.1 117.3 ± 41.2 114.6 ± 46.4 113.4 ± 40.2 0.58
   Albumin (g/dL) 4.1 ± 0.4 4.2 ± 0.4 4.1 ± 0.5 3.9 ± 0.6 0.001
   Calcium (mg/dL) 9.1 ± 0.5 9.2 ± 0.5 9.1 ± 0.5 9.1 ± 0.5 0.45
   Phosphate (mg/dL) 3.7 ± 0.7 3.7 ± 0.6 3.7 ± 0.6 3.8 ± 0.5 0.54
   Cholesterol (mg/dL) 166.2 ± 41.1 167.1 ± 38.8 165.1 ± 41.5 171.4 ± 53.9 0.48
   Triglycerides (mg/dL) 165.2 ± 102.5 160.9 ± 97.2 165.1 ± 103.7 203.7 ± 126.1 0.02
   HDL-C (mg/dL) 49.0 ± 14.9 49.3 ± 15.4 48.8 ± 14.6 48.8 ± 14.2 0.85
   LDL-C (mg/dL) 89.0 ± 32.1 90.5 ± 30.2 88.0 ± 32.3 89.1 ± 44.1 0.48
   hs-CRP (mg/dL) 0.60 (0.26-1.60) 0.60 (0.29-1.60) 0.60 (0.20-1.70) 0.69 (0.40-1.25) 0.90
Data are presented as mean ± standard deviation, number (%), or median (interquartile range).
ASCVD, atherosclerotic cardiovascular disease; BP, blood pressure; CKD, chronic renal disease; eGFR, estimated glomerular filtration rate; HDL-C, high-density 
lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; hs-CRP, high-sensitivity C-reactive protein. 
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in cause of CKD among the three groups. Regarding use 
of other lipid-lowering drugs, the high-intensity group 
was taking less ezetimibe and more fibrates than the low-
intensity group. In the laboratory data, the high-intensity 
group showed higher level of proteinuria and lower level 
of serum albumin than the low-intensity group. There 
were no differences in lipid profiles among groups ex-
cept in terms of triglyceride level; patients in the high-
intensity group showed higher level of TG than those in 
the low-intensity group. The ASCVD risk score, Charlson 
Comorbidity Index, and prevalence of comorbidities 
such as diabetes, hypertension, coronary artery disease, 
congestive heart failure, and peripheral artery disease 
were similar among groups.
Risk of kidney disease progression according to intensity 
of statin therapy
During a median follow-up of 39.9 (25.4-61.6) months, 
102 (23.9%), 138 (23.2%), and 15 (30.0%) renal outcome 
events occurred in low-, moderate-, and high-intensity 
groups (P for trend = 0.74), respectively. The crude inci-
dence rate of doubling of serum creatinine, ≥ 50% decline 
in eGFR, and initiation of dialysis or kidney transplanta-
tion was higher in the high-intensity group than in the 
low-intensity group without statistical significance (Fig. 
2). However, Kaplan-Meier analysis showed no signifi-
cant difference in time to first adverse kidney outcome 
among statin intensity groups (Fig. 3). In multivariable 
Cox analysis adjusted for demographic factors of age, 
sex, BMI, SBP, smoking status, income status, comorbidi-
ties (hypertension, diabetes, and CVDs), laboratory data 
(eGFR, proteinuria, and lipid profiles), and use of other 
lipid-lowering agents (ezetimibe or fibrates), use of high- 
or moderate-intensity statin was not associated with risk 
of CKD progression compared with use of low-intensity 
statin. The corresponding HRs (95% CIs) were 1.15 (0.60-
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Figure 2. Incidence of renal events across statin intensity groups. 
eGFR, estimated glomerular filtration rate; sCr, serum creatinine.














































Figure 3. Kaplan-Meier curve for progression of chronic kidney 
disease according to statin therapy intensity.
Table 2. Association between progression of chronic kidney disease and statin therapy intensity 
Model 1 Model 2 Model 3 Model 4
Cases (%)a HR (95% CI) P HR (95% CI) P HR (95% CI) P HR (95% CI) P
Low 102 (23.9) Reference
Moderate 138 (23.2) 0.95 (0.74-1.23) 0.71 1.00 (0.77-1.29) 0.99 0.94 (0.73-1.23) 0.66 0.97 (0.72-1.30) 0.82
High 15 (30.0) 1.26 (0.73-2.17) 0.40 1.29 (0.75-2.23) 0.36 1.34 (0.77-2.34) 0.30 1.15 (0.60-2.20) 0.69
CI, confidence interval; HR, hazard ratio.
Model 1: unadjusted; Model 2: adjusted for age, sex, body mass index, and systolic blood pressure; Model 3: adjusted for Model 2 + smoking, income status, 
comorbidities (histories of hypertension, diabetes, and cardiovascular disease); Model 4: adjusted for Model 3 + laboratory factors (estimated glomerular filtration 
rate; proteinuria; lipid profiles including triglycerides, high-density lipoprotein cholesterol, and low-density lipoprotein cholesterol) and use of other lipid-lowering 
agents (ezetimibe or fibrate).
aP for trend = 0.74.
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dition, the annual eGFR decline rate was not different 
among the three groups (-1.19 ± 0.24, -1.58 ± 0.16, and 
-0.16 ± 0.59 mL/min/1.73 m2/yr in low-, moderate-, and 
high-intensity statin groups, respectively; P = 0.06). When 
high- and moderate-intensity statins were grouped to-
gether, no significant association was observed between 
statin intensity and primary outcome (HR, 1.03; 95% CI, 
0.77-1.38; Supplementary Table 2).
In addition, the association between statin intensity 
and change in proteinuria during follow-up was evalu-
ated. Proteinuria level was not significantly different 
among statin intensity groups during the follow-up pe-
riod (P = 0.64; Supplementary Fig. 1).
Subgroup analyses
We further evaluated the association between statin 
therapy intensity and CKD progression in subgroups 
stratified by age (< 60 years vs. ≥ 60 years), sex (female vs. 
male), eGFR category (15-45 vs. ≥ 45 mL/min/1.73 m2), 
and ASCVD risk score (< 7.5% vs. ≥ 7.5%). There were no 
significant interactions between stratified variables and 
statin therapy intensity group in terms of CKD progres-
sion. This result suggests that the association was consis-
tent regardless of age, sex, eGFR, and ASCVD risk score 
(Fig. 4).
Discussion 
In the present study, we investigated the association 
between statin therapy intensity and CKD progression in 
patients with CKD. Despite the crucial role of intensity-
based statin therapy in preventing cardiovascular events, 
low-, moderate-, or high-intensity statin therapies were 
similarly associated with risk of adverse kidney outcome. 
This association was consistent regardless of age, sex, 
eGFR category, and ASCVD risk score.
Dyslipidemia is an important risk factor for adverse 
cardiovascular outcome in patients with and without 
CKD [24]. Previous meta-analyses have shown that statin 
therapies largely contribute to reduced atherosclerotic 
cardiovascular events and related mortality in patients 
with non-dialysis-dependent CKD [25,26]. In addition, 
dyslipidemia is associated with more rapid loss of kidney 
function in people without kidney disease. Patients with 
kidney disease are more likely to have hyperlipidemia, 
although not all patients with elevated lipid levels have 
kidney disease [27,28]. In experimental studies, hyper-
lipidemia may exacerbate preexisting kidney disease by 
causing direct injury to the glomerular basement mem-
brane [29]. In contrast, statins may improve kidney func-
tion by improving endothelial function to increase renal 
perfusion [30]. Furthermore, statins reduce proteinuria 
by attenuating renal inflammation and fibrosis in the tu-
bulointerstitium [31]. Although lipid accumulation and 
lipotoxicity may lead to kidney injury in experimental 
animal models, there is insufficient evidence supporting 
an effect of lipid profile abnormality on kidney function 
in humans [32]. Furthermore, epidemiologic studies have 
yielded conflicting results on the relationship between 
statins and kidney disease progression among patients 
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Figure 4. Subgroup analysis. 
ASCVD, atherosclerotic cardiovascular 
disease; eGFR, estimated glomerular 
filtration rate.
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fects of statins on kidney disease outcomes [33,34]. How-
ever, previous studies were based on post hoc analyses 
of cardiovascular benefits of statin therapy, and the ef-
fects on kidney function were modest. Moreover, studies 
suggesting the reno-protective effects of statins mainly 
included patients with prevalent CVD, and several other 
studies showed that statins have no effect on kidney 
function in CKD patients without CVD [35,36]. Therefore, 
statin therapy may decrease the rate of kidney function 
decline mainly in patients with prevalent CVD. However, 
the clinical significance of this effect remains unclear.
Recently, statin therapies of differing intensity are being 
recommended. The ACC/AHA guidelines emphasize dif-
ferent statin therapy intensities in patients with varying 
risks of ASCVD [14]. In this regard, the dose-dependent 
relationship between statin therapy intensity and renal 
outcome can be hypothesized [37]. Sanguankeo et al 
[12] reported that high-intensity statin therapy improved 
eGFR in patients with CKD compared to a control group, 
but moderate- to low-intensity statin therapies were 
not associated with improved eGFR. They also showed 
that LDL-C reduction had a significant association with 
changes in eGFR; the magnitude of eGFR increase was 
well correlated with decrease in LDL-C concentration. In 
line with our study, however, they showed no significant 
association between statin therapy intensity and hard 
study endpoints, such as 50% eGFR reduction or devel-
opment of ESRD. Possible reasons for the nonsignificant 
association between statin therapy intensity and hard 
renal events in this study are suggested. First, most previ-
ous studies that reported the effects of statins on renal 
function were post-hoc analyses of original studies that 
aimed to examine the cardiovascular benefits of statin 
therapy. Thus, almost all study subjects had preexisting 
CVD. However, in the present study, only 10% of study 
participants had previous CVD at baseline. It is pos-
sible that the protective effect of statins might not have 
been pronounced in our study cohort. Hence, subgroup 
analysis stratified by low vs. high ASCVD risk scores was 
performed; however, there was still no significant rela-
tionship between statin therapy intensity and renal event. 
Second, the positive effect of statins on declining kidney 
function may be attenuated in the presence of other risk 
factors for CKD progression, such as high BP. Hyperten-
sion is one of the strongest risk factors for kidney func-
tion decline. A previous study showed that the benefi-
cial effect of statins on preservation of kidney function 
was weaker in people with higher SBP [38]. This result 
suggests that other risk factors can modify the effect of 
statins on kidney function. Third, previous studies indi-
cated that statin therapy may lead to unintended acute 
kidney injury. In particular, use of high-intensity statin 
therapy was associated with an increased rate of acute 
kidney injury diagnosis during hospital admissions [18]. 
Therefore, the possible harmful effect of statin therapy 
might have hindered the reno-protective effect of statins. 
Nevertheless, statins also may have pleiotropic effects fa-
vorable for reducing CKD progression, such as lowering 
oxidative stress, reducing inflammation, and stabilizing 
atherosclerotic plaques [39]. Thus, further studies are 
warranted to validate the effect of statins on renal out-
comes.
Although we did not observe significant association 
between statin intensity and adverse kidney outcome, 
our findings remain valuable. First, it is well-known that 
statin therapy in patients with CKD is not as effective as 
in people without CKD. The reason for this is unclear, but 
we thought that statin intensity might modify the rela-
tionship between statin use and adverse clinical outcome 
in patients with CKD. This prompted us to analyze this 
association in depth using a cohort database involving 
only patients with CKD. Although we could not assert a 
causal relationship, our findings suggest that the lower 
effectiveness of statin therapy in patients with CKD may 
not be related to statin intensity. Second, there is con-
cern regarding the possible harmful association of high-
intensity statins with acute kidney injury [40]. However, 
our study showed that high- or low-intensity statin use 
was similarly associated with risk of CKD progression. 
This indicates that long-term kidney outcomes may not 
be affected by statin intensity.
This study has several limitations. First, due to its ob-
servational design, the causal relationship between statin 
therapy intensity and kidney function could not be deter-
mined. Second, patients with ESRD requiring dialysis or 
those who had received kidney transplantation were not 
included. Thus, the study results cannot be generalized 
to these patients. Third, only baseline statin therapy was 
used in the analysis; thus, the study results cannot reflect 
changes in statin use over time. Furthermore, changes 
in LDL-C level according to statin intensity could not be 
evaluated because patients had been treated with statin 
Kidney Res Clin Pract   Vol. 39, No. 1, March 2020
100 www.krcp-ksn.org
therapy before study enrollment. The beneficial effects of 
high-intensity statin therapy were linked to higher reduc-
tion in LDL-C level [17]. Thus, it could not be determined 
whether high-intensity statin therapy with a large reduc-
tion in LDL-C level has a reno-protective effect. Fourth, 
the proportion of participants in the high-intensity statin 
therapy group was relatively small. The 2013 KDIGO 
lipid guidelines recommend statins for patients aged ≥ 
50 years with CKD and with eGFR < 60 mL/min/1.73 m2, 
but it does not specify statin intensity dosing recommen-
dations [41]. Thus, most patients with CKD take statins 
irrespective of dose based on statin intensity. In the pres-
ent study, ASCVD risk scores were not significantly dif-
ferent among statin therapy intensity groups, suggesting 
that statins were not prescribed based on intensity-based 
dosing recommendations. This may have resulted in a 
decreased effect of statins on kidney function. Finally, 
the study cohort included a single ethnic group, with all 
participants being Korean. Thus, the results should be 
interpreted with caution, and our findings may not be 
generalized to other ethnic groups. 
In conclusion, among Korean adults with CKD, we did 
not observe any significant association between statin 
therapy intensity and CKD progression. However, the 
findings obtained from our observational study do not 
provide sufficient evidence on this issue. Given the im-
portance of treating dyslipidemia in patients with CKD, 
further large and well-designed randomized controlled 
trials are needed to clearly determine the effects of inten-
sity-based statin therapy on kidney function.
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